Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MLYS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMineralys pays $200M to eliminate lorundrostat royalty, raises $250M ahead of Dec PDUFA
Filed August 11, 2026 · Period ending August 5, 2026 · ~1 min read
Key Changes
-
high
Paid Tanabe $200M upfront to eliminate ongoing royalty obligations on lorundrostat sales, converting to capped milestone payments of up to $255M tied to first commercial sale and annual sales targets plus up to $10M for a potential second indication.
Exhibit 99.1 view on EDGAR → -
high
Raised approximately $150M gross proceeds via follow-on offering of 5.66M shares and drew initial $100M tranche from up to $500M Pharmakon term loan facility to fund commercial launch preparations.
Exhibit 99.1 view on EDGAR → -
high
Q2 2026 net loss of $241.1M (vs. $43.3M prior year) driven by $200M Tanabe payment; cash position of $661.4M at quarter-end expected to fund operations into 2028.
Exhibit 99.1 view on EDGAR → -
medium
Appointed Dr. James J. Ferguson III as Chief Medical Officer effective August 10, 2026, bringing 35+ years of cardiovascular drug development experience from Amgen, AstraZeneca, and The Medicines Company.
Item 5.02 verify on EDGAR → -
low
Prior CMO Dr. David Rodman transitions to full-time Strategic Advisor role; Board determined he no longer qualifies as an officer under SEC rules based on new responsibilities.
Item 5.02 verify on EDGAR →
Summary
Mineralys executed a major balance sheet and capital structure repositioning in Q2 2026 ahead of lorundrostat's December 22, 2026 PDUFA date. The company paid Tanabe $200 million upfront to eliminate ongoing royalty obligations, converting future economics into capped milestone payments of up to $255 million tied to commercial sales thresholds.
This restructuring improves long-term unit economics by removing a percentage-based royalty drag on future revenues. To fund the buyout and commercial launch preparations, Mineralys raised approximately $250 million through a $150 million follow-on equity offering (5.66 million shares) and an initial $100 million draw from a new up to $500 million Pharmakon term loan facility.
The Q2 2026 net loss of $241.1 million reflects the $200 million Tanabe payment as a one-time R&D expense; excluding that, operating expenses increased modestly to support headcount growth and launch readiness. Cash, cash equivalents, and investments stood at $661.4 million at quarter-end, which management expects will fund operations into 2028. The company also appointed Dr. Terry Ferguson as Chief Medical Officer, bringing deep cardiovascular commercialization experience from Amgen and AstraZeneca as the company prepares for potential approval and launch. The capital raise, royalty buyout, and leadership addition position Mineralys for a commercial transition if lorundrostat receives FDA approval in December.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Mineralys issued Q2 2026 financial results and corporate update via press release.
Added in current filing · verify on EDGAR →
On August 11, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2026 and provided a corporate update.
The company disclosed its second quarter 2026 financial results through a press release. The 8-K body does not contain the actual financial figures; those are in the attached Exhibit 99.1 press release, which is not included in the provided text.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On August 5, 2026, Dr. Rodman entered into an amendment to his Amended and Restated Employment Letter Agreement (the Amendment) to reflect his transition into a Strategic Advisor role, effective August 10, 2026.
Dr. Rodman's employment agreement was amended to formalize his transition to Strategic Advisor. The amendment is attached as Exhibit 10.1, though specific compensation or term details are not disclosed in the 8-K body.
Event · Exhibit 99.1
Q2 2026 results: $200M Tanabe royalty buyout, $150M equity raise, $100M debt draw; PDUFA date Dec 22, 2026; new CMO appointed.
Added in current filing · view on EDGAR →
Appointed James J. “Terry” Ferguson III, M.D., as CMO, effective August 10, 2026, succeeding David Rodman, M.D., who will stay on with the Company as a full-time Strategic Advisor. Terry brings more than 35 years of experience in cardiovascular medicine and drug development, including serving as Cardiovascular Therapeutic Area Head at Amgen, nearly a decade in cardiovascular leadership roles at AstraZeneca and The Medicines Company, as well as more than two decades on the faculty of the Texas Heart Institute.
Dr. Terry Ferguson was appointed Chief Medical Officer effective August 10, 2026, succeeding Dr. David Rodman, who transitions to a full-time Strategic Advisor role. Ferguson brings over 35 years of cardiovascular medicine and drug development experience from Amgen, AstraZeneca, The Medicines Company, and the Texas Heart Institute. He will lead medical and late-stage clinical activities as the company prepares for lorundrostat's commercial launch.
Added in current filing · view on EDGAR → · paraphrased
Research and development (R&D) expenses for the quarter ended June 30, 2026 were $221.4 million, compared to $38.3 million for the quarter ended June 30, 2025. The increase in R&D expenses was primarily due to the $200.0 million upfront payment to Tanabe in June 2026 in connection with the license agreement amendment. ... General and administrative (G&A) expenses were $24.7 million for the quarter ended June 30, 2026, compared to $8.5 million for the quarter ended June 30, 2025. ... Net loss was $241.1 million for the quarter ended June 30, 2026, compared to $43.3 million for the quarter ended June 30, 2025. ... Cash, cash equivalents and investments were $661.4 million as of June 30, 2026, compared to $656.6 million as of December 31, 2025.
Q2 2026 net loss was $241.1 million versus $43.3 million in Q2 2025, driven primarily by the $200 million Tanabe upfront payment. R&D expenses rose to $221.4 million from $38.3 million, and G&A expenses increased to $24.7 million from $8.5 million, reflecting headcount growth and commercial launch preparations.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 12, 2026 · How we verify